BioCryst Pharmaceuticals announces sale of common stock shares

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Nov 17 2009BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

BioCryst also intends to grant the underwriters a 30-day option to purchase up to an aggregate of 750,000 additional shares of common stock to cover over-allotments, if any. All of the shares in the offering are to be sold by BioCryst. Morgan Stanley will be acting as the sole book-runner for the offering, with JMP Securities and Oppenheimer & Co. acting as co-managers.

Source:

BioCryst Pharmaceuticals, Inc.

Posted in:

Tags: , , , , ,

Comments (0)

Suggested Reading

New urine-based test improves identification of high-grade prostate cancer
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Study highlights global fertility decline and its implications for the future
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain
Lancet Commission predicts sharp increase in global prostate cancer cases
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Research quantifies impact of childhood obesity on long-term health and life expectancy
Sensing a Healthier Future with Sustainable Nanomaterials and Biosensors

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
St. Jude researchers unveil mechanisms to block PXR and enhance drug potency